New Haven biotech Kleo Pharmaceuticals is collaborating with a South Korean company to advance a potential drug targeting COVID-19.
The Science Park-based startup said it was working with South Korea’s Green Cross LabCell on a treatment that would combine Kleo’s ARM (antibody recruiting molecule) technology with that company’s “natural killer” cell therapies.